KALYDECO is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was granted...
Stony Brook University has entered into a multiyear research partnership with the global pharmaceutical company Sanofi to develop a potential treatment for tuberculosis and other bacterial infections. The university didn't disclose the terms...
Austin-based Local, Organic Food Delivery Company Expands Service to DFW Metroplex, Headquarters North Texas Operations in New Allen Local Food Hub DALLAS -- Greenling, a web-based home delivery service of fresh, local and...
Simple guidelines for increasing safety compliance in the workplace CINCINNATI -- In 2010, more than 3.9 million workplace injuries and illnesses were reported, many of which were preventable. No significant changes to these...
NEW YORK -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per...
DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/0a092f/antibotics_and_ant) has announced the addition of John Wiley and Sons Ltd's new book "Antibotics and Antibotic Resistance" to their offering. This book, which is the translated version of a...
DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/df7978/antibiotic_resista) has announced the addition of the "Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance" report to their offering. This report gives a...
DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/454d3a/product_profiles) has announced the addition of the "Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market" report to their offering. In the last two...
-Ganetespib and docetaxel display complementary cell cycle inhibition effects- -Combination of ganetespib with microtubule stabilizers (docetaxel and paclitaxel) or destabilizers (vincristine) results in synergistic anticancer activity- -Ganetespib and docetaxel combination currently being studied...
San Diego-based startup Elevation Pharmaceuticals Inc. has raised $32 million in a second round of financing that will help the company advance its lead product candidate, an aerosol therapy for people with chronic...
DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/0d57e5/bronchitis_therape) has announced the addition of GlobalData's new report "Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. GlobalData, the industry analysis specialist, has released...
DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/3be296/ent_disorders_mark) has announced the addition of the "ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance" report to their offering....
Need help preparing for the applied knowledge test? Questions from Examdoctor (examdoctor.co.uk) are provided below to help GP registrars prepare for the applied knowledge test (AKT). The questions are produced according to the...
Astellas Pharma, Inc. and Theravance, Inc. have announced that Astellas Pharma has exercised its right to terminate the global license, development and commercialization agreement for VIBATIV(R) (telavancin) for injection, a bactericidal, once-daily lipoglycopeptide...
Patent Covers AzaSite([R]), AzaSite Xtra([TM]) and AzaSite Plus([TM]) ALAMEDA, Calif. -- InSite Vision Incorporated (OTCBB: INSV) today announced that the Japanese Patent Office has issued a Notice to Patent with claims covering the...
4th Quarter 2011 Total CUBICIN Net Product Revenues Of $200.9 Million, Up 25% Over 4th Quarter 2010 U.S. CUBICIN Full Year 2011 Net Product Revenues of $698.8 Million, Up 17% Over 2010 Scheduled...
InSite Vision to Vigorously Defend AzaSite([R]) Patents ALAMEDA, Calif. -- InSite Vision Incorporated (OTCBB:INSV) today announced that the University of California, San Francisco (UCSF) has appealed the judgment of the United States Patent...
First Hospital in Houston to Offer Innovative Procedure HOUSTON -- St. Luke's Episcopal Hospital (St. Luke's) is the first hospital in Houston to offer bronchial thermoplasty, an innovative procedure for the treatment of...
TARRYTOWN, N.Y. -- Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced that Alan W. Dunton, M.D., has been appointed to the Company's Board of Directors and named Non-Executive...
Biopharmaceutical Industry Veteran to Help Advance Strategic Value of Tetraphase's Promising Portfolio of Potent New Antibiotics WATERTOWN, Mass. -- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new...